Developer docs
API playgroundTry for free, no card

Search company profiles

Semalytix

Full company profile

uuid00029kx

Namestring
Semalytix
Legal namestring
Semalytix GmbH
Websiteurl
semalytix.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Semalytix GmbH is a Bielefeld, Germany-based private company that builds Project Atlas, an agentic AI platform designed to decode the global patient voice for pharmaceutical decision-making. The platform continuously ingests unstructured patient discourse from social sources and private forums across 26 languages and 144 countries, applies supervised AI and knowledge graphs to verify that posts originate from real patients (reported 94–95%+ accuracy), and returns structured, provenance-traceable answers to plain-English questions posed by pharma teams. Atlas is augmented by three purpose-built Sentinel Agents — Safety Sentinel for pharmacovigilance signal detection, Adherence Sentinel for discontinuation and persistence intelligence, and Outbreak Sentinel for respiratory disease surveillance — covering roughly 100 disease areas across oncology, immunology, cardiovascular, neuroscience, infectious diseases, and rare/specialty conditions.

The technology stack is engineered for regulatory-grade defensibility: the platform operates on an aggregate-only basis aligned to the POMELO protocol (Protocol for sOcial MEdia Listening Online), which was co-developed by CTO Philipp Cimiano through the Pistoia Alliance, and is structured so that no individual post meets ICSR validity criteria at point of access — delivering "awareness without obligation" under EMA GVP VI Rev 2. Documented technical performance includes safety signal detection 6–9 months earlier than FAERS spontaneous reporting (median across 19 retrospective cases), adherence signals 6–10 weeks ahead of claims-data refill gaps, and outbreak signals 1–6 weeks ahead of WHO/CDC/ECDC feeds.

Semalytix sells on an enterprise SaaS subscription model with quote-based, portfolio-tiered pricing; the GTM is direct field sales into pharmaceutical companies, with "Book a demo" CTAs and a 30-minute Atlas walkthrough as the primary conversion mechanism. Customers include top-10 pharma and specialty pharmaceutical companies deploying Atlas across Medical, Commercial, HEOR and Pharmacovigilance teams, with named use cases spanning safety, launch excellence, competitive intelligence, RWE, adherence, and patient centricity. The company is venture-backed (most recent round a €5.7 million raise led by Holland Capital in October 2025), has 51–100 employees, and is led by co-founders Janik Jaskolski (CEO) and Philipp Cimiano (CTO), alongside co-founders Matthias Hartung (CRDO) and Roman Klinger.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBielefeld, Germany
HQ citystring
Bielefeld
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical AI platform, patient voice intelligence, pharmacovigilance signal detection, medication adherence analytics, social media listening pharma
Industry2 codes
PRIMARYHLAJABAN
Data Integration, Interoperability & Reporting (ELR/HIE/CDC/NNDSS)
Healthcare & Life Sciences/Public Health, Government & Regulators/Disease Surveillance, Epidemiology & Outbreak Response
SECONDARYHLACAKAK
Medication Safety, Pharmacovigilance & Adverse Event Reporting IT
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
NAICS code2 codes
  • Medical and Diagnostic Laboratories6215
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Pharmaceutical AI Analytics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1SaaS/Platform Subscription
TypeSubscription Recurring
Description

Agentic AI platform sold to pharmaceutical companies on a subscription basis. Pricing appears quote-based, likely tiered by portfolio size, drug count, and Sentinel Agent deployment. Used by top-10 pharma across Medical, Commercial, HEOR and PV teams.

semalytix.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Enterprise SaaS platform with quote-based pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing appears portfolio-based, scaling with number of marketed drugs, launches, and active trials. ROI calculators on website suggest value-based pricing tied to measurable outcomes like earlier safety signal detection and recoverable adherence revenue.

semalytix.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Semalytix provides Project Atlas, an agentic AI platform that decodes the global patient voice from social and forum sources in 26 languages across 144 countries, delivering continuous, governed intelligence to pharmaceutical companies. The platform is augmented by three Sentinel Agents: Safety Sentinel (aggregate-only pharmacovigilance signal detection), Adherence Sentinel (discontinuation driver intelligence 6–10 weeks ahead of claims data), and Outbreak Sentinel (respiratory disease surveillance 1–6 weeks ahead of WHO/CDC/ECDC). All outputs include full provenance and comply with the POMELO protocol and GDPR aggregate-only architecture.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Safety signal detection 6-9 months earlier than spontaneous reporting (FAERS), with median 7-9 months lead time across 19 retrospective cases
+6 more records
Product overview1 text field

Semalytix offers a platform-plus-modules architecture centered on Project Atlas, an agentic AI platform that decodes the global patient voice for pharmaceutical decision-making. The platform is augmented by three specialized Sentinel Agents: Safety Sentinel for pharmacovigilance signal detection, Adherence Sentinel for patient persistence monitoring, and Outbreak Sentinel for respiratory disease surveillance. Atlas processes patient discourse across 95+ diseases in 26 languages and 144 countries, providing continuous intelligence across the drug development lifecycle from R&D through launch and lifecycle management.

Product and service1 record
1Project Atlas
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston Children's Hospital-affiliated real-time disease surveillance system aggregating public digital sources to detect emerging outbreaks. Comparable in mission and data approach to Outbreak Sentinel, though academic/non-commercial.

TypeEmerging player
Description

Global physician social network monetizing physician and patient insights for pharma research. Overlaps with Semalytix's qualitative patient-voice use cases for medical affairs and HEOR, though data source is community-based rather than open social.

TypeEmerging player
Description

Patient-reported outcomes platform capturing longitudinal treatment and symptom experience, often used in pharma real-world evidence. Comparable in patient-voice sourcing, though primarily survey/community-based versus Atlas's open social listening.

TypeDirect peer
Description

Outbreak intelligence platform using AI on global news, airline and public-health data for early outbreak warning. Most directly comparable peer for Semalytix's Outbreak Sentinel, with overlapping real-time, multilingual, multi-country disease surveillance.

TypeBroad incumbent
Description

Enterprise customer experience and social-listening suite with pharma customers. Comparable at the social-listening layer but lacks the patient-verification and PV-compliance depth Semalytix claims.

6Oracle Health (formerly Cerner)
TypeBroad incumbent
Description

Owner of Oracle Argus, the dominant pharmacovigilance safety database, plus a growing RWE and clinical footprint. Could integrate AI-driven patient signals into Argus, directly threatening Safety Sentinel's positioning inside pharma PV organizations.

TypeBroad incumbent
Description

Dominant pharma SaaS provider (Vault Safety, Vault CRM, Medical) with deep enterprise pharma relationships. Overlaps directly with Semalytix's PV and medical-affairs use cases and could natively embed patient-voice features into its platform.

TypeBroad incumbent
Description

Global CRO and health-IT incumbent selling social listening, pharmacovigilance and real-world evidence solutions into the same top-10 pharma accounts Semalytix targets. It competes via bundled contracts and could build or acquire supervised patient-voice AI to defend its footprint.

TypeBroad incumbent
Description

Enterprise consumer intelligence and social-listening platform used by pharma brand and CI teams. Competes on the same dashboards Semalytix targets, though its supervised patient-verification accuracy and pharma-specific compliance posture are weaker.

TypeDirect peer
Description

Largest patient community platform, hosting condition-specific patient forums and offering structured insights to pharma. Directly comparable for the patient-voice intelligence layer Semalytix provides via Atlas, especially in rare and chronic conditions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Semalytix

Pharmaceutical AI Analyticssemalytix.com

What Semalytix does

Semalytix GmbH is a Bielefeld, Germany-based private company that builds Project Atlas, an agentic AI platform designed to decode the global patient voice for pharmaceutical decision-making. The platform continuously ingests unstructured patient discourse from social sources and private forums across 26 languages and 144 countries, applies supervised AI and knowledge graphs to verify that posts originate from real patients (reported 94–95%+ accuracy), and returns structured, provenance-traceable answers to plain-English questions posed by pharma teams. Atlas is augmented by three purpose-built Sentinel Agents — Safety Sentinel for pharmacovigilance signal detection, Adherence Sentinel for discontinuation and persistence intelligence, and Outbreak Sentinel for respiratory disease surveillance — covering roughly 100 disease areas across oncology, immunology, cardiovascular, neuroscience, infectious diseases, and rare/specialty conditions.

The technology stack is engineered for regulatory-grade defensibility: the platform operates on an aggregate-only basis aligned to the POMELO protocol (Protocol for sOcial MEdia Listening Online), which was co-developed by CTO Philipp Cimiano through the Pistoia Alliance, and is structured so that no individual post meets ICSR validity criteria at point of access — delivering "awareness without obligation" under EMA GVP VI Rev 2. Documented technical performance includes safety signal detection 6–9 months earlier than FAERS spontaneous reporting (median across 19 retrospective cases), adherence signals 6–10 weeks ahead of claims-data refill gaps, and outbreak signals 1–6 weeks ahead of WHO/CDC/ECDC feeds.

Semalytix sells on an enterprise SaaS subscription model with quote-based, portfolio-tiered pricing; the GTM is direct field sales into pharmaceutical companies, with "Book a demo" CTAs and a 30-minute Atlas walkthrough as the primary conversion mechanism. Customers include top-10 pharma and specialty pharmaceutical companies deploying Atlas across Medical, Commercial, HEOR and Pharmacovigilance teams, with named use cases spanning safety, launch excellence, competitive intelligence, RWE, adherence, and patient centricity. The company is venture-backed (most recent round a €5.7 million raise led by Holland Capital in October 2025), has 51–100 employees, and is led by co-founders Janik Jaskolski (CEO) and Philipp Cimiano (CTO), alongside co-founders Matthias Hartung (CRDO) and Roman Klinger.

Semalytix firmographics

Firmographics
Name
Semalytix
Legal name
Semalytix GmbH
Website
https://semalytix.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Semalytix industry classification

Industry
Product category
Pharmaceutical AI Analytics
NAICS
Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAJABAN
Data Integration, Interoperability & Reporting (ELR/HIE/CDC/NNDSS)
Healthcare & Life Sciences/Public Health, Government & Regulators/Disease Surveillance, Epidemiology & Outbreak Response
SECONDARYHLACAKAK
Medication Safety, Pharmacovigilance & Adverse Event Reporting IT
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT

Keywords

  • Pharmaceutical AI platform
  • Patient voice intelligence
  • Pharmacovigilance signal detection
  • Medication adherence analytics
  • Social media listening pharma

Where Semalytix is headquartered

Location

Headquarters

HQ city
Bielefeld
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Semalytix business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. SaaS/Platform Subscription: Agentic AI platform sold to pharmaceutical companies on a subscription basis. Pricing appears quote-based, likely tiered by portfolio size, drug count, and Sentinel Agent deployment. Used by top-10 pharma across Medical, Commercial, HEOR and PV teams.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise SaaS platform with quote-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Semalytix product offering

Product offering

Core offering

Semalytix provides Project Atlas, an agentic AI platform that decodes the global patient voice from social and forum sources in 26 languages across 144 countries, delivering continuous, governed intelligence to pharmaceutical companies. The platform is augmented by three Sentinel Agents: Safety Sentinel (aggregate-only pharmacovigilance signal detection), Adherence Sentinel (discontinuation driver intelligence 6–10 weeks ahead of claims data), and Outbreak Sentinel (respiratory disease surveillance 1–6 weeks ahead of WHO/CDC/ECDC). All outputs include full provenance and comply with the POMELO protocol and GDPR aggregate-only architecture.

Product overview

Semalytix offers a platform-plus-modules architecture centered on Project Atlas, an agentic AI platform that decodes the global patient voice for pharmaceutical decision-making. The platform is augmented by three specialized Sentinel Agents: Safety Sentinel for pharmacovigilance signal detection, Adherence Sentinel for patient persistence monitoring, and Outbreak Sentinel for respiratory disease surveillance. Atlas processes patient discourse across 95+ diseases in 26 languages and 144 countries, providing continuous intelligence across the drug development lifecycle from R&D through launch and lifecycle management.

Differentiator

Problem solved

Functional benefit

Products and services

  • Project Atlas

Quantifiable outcome

  • Safety signal detection 6-9 months earlier than spontaneous reporting (FAERS), with median 7-9 months lead time across 19 retrospective cases
  • +6 more outcomes

Companies that use Semalytix

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles2 records

Semalytix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Semalytix partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Semalytix competitors and assessment

Company assessment

Direct peers

  • HealthMap: Boston Children's Hospital-affiliated real-time disease surveillance system aggregating public digital sources to detect emerging outbreaks. Comparable in mission and data approach to Outbreak Sentinel, though academic/non-commercial.
  • BlueDot: Outbreak intelligence platform using AI on global news, airline and public-health data for early outbreak warning. Most directly comparable peer for Semalytix's Outbreak Sentinel, with overlapping real-time, multilingual, multi-country disease surveillance.
  • Inspire: Largest patient community platform, hosting condition-specific patient forums and offering structured insights to pharma. Directly comparable for the patient-voice intelligence layer Semalytix provides via Atlas, especially in rare and chronic conditions.

Emerging players

  • Sermo: Global physician social network monetizing physician and patient insights for pharma research. Overlaps with Semalytix's qualitative patient-voice use cases for medical affairs and HEOR, though data source is community-based rather than open social.
  • PatientsLikeMe: Patient-reported outcomes platform capturing longitudinal treatment and symptom experience, often used in pharma real-world evidence. Comparable in patient-voice sourcing, though primarily survey/community-based versus Atlas's open social listening.

Broad incumbents

  • Sprinklr: Enterprise customer experience and social-listening suite with pharma customers. Comparable at the social-listening layer but lacks the patient-verification and PV-compliance depth Semalytix claims.
  • Oracle Health (formerly Cerner): Owner of Oracle Argus, the dominant pharmacovigilance safety database, plus a growing RWE and clinical footprint. Could integrate AI-driven patient signals into Argus, directly threatening Safety Sentinel's positioning inside pharma PV organizations.
  • Veeva Systems: Dominant pharma SaaS provider (Vault Safety, Vault CRM, Medical) with deep enterprise pharma relationships. Overlaps directly with Semalytix's PV and medical-affairs use cases and could natively embed patient-voice features into its platform.
  • IQVIA: Global CRO and health-IT incumbent selling social listening, pharmacovigilance and real-world evidence solutions into the same top-10 pharma accounts Semalytix targets. It competes via bundled contracts and could build or acquire supervised patient-voice AI to defend its footprint.
  • Brandwatch (Cision): Enterprise consumer intelligence and social-listening platform used by pharma brand and CI teams. Competes on the same dashboards Semalytix targets, though its supervised patient-verification accuracy and pharma-specific compliance posture are weaker.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Semalytix social profiles

Digital presence

Semalytix compliance and trust

Trust signal

Compliance2 records

Semalytix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Semalytix leadership team

Management profile

Number of profiles

Profiles5 records

Semalytix funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Semalytix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Semalytix

What does Semalytix do?

Semalytix provides Project Atlas, an agentic AI platform that decodes the global patient voice from social and forum sources in 26 languages across 144 countries, delivering continuous, governed intelligence to pharmaceutical companies. The platform is augmented by three Sentinel Agents: Safety Sentinel (aggregate-only pharmacovigilance signal detection), Adherence Sentinel (discontinuation driver intelligence 6–10 weeks ahead of claims data), and Outbreak Sentinel (respiratory disease surveillance 1–6 weeks ahead of WHO/CDC/ECDC). All outputs include full provenance and comply with the POMELO protocol and GDPR aggregate-only architecture.

Is Semalytix a public or private company?

Semalytix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Semalytix founded?

Semalytix was founded in 2015. It employs 11 to 50 people.

Where is Semalytix based?

Semalytix is headquartered in Bielefeld, Germany, in the Europe region.

How does Semalytix make money?

One revenue line is on record: saaS/Platform Subscription.

Who are Semalytix's main competitors?

Direct peers on record are HealthMap, BlueDot and Inspire. Emerging players are Sermo and PatientsLikeMe. Broad incumbents are Sprinklr, Oracle Health (formerly Cerner), Veeva Systems, IQVIA and Brandwatch (Cision).

Does Semalytix have an API?

No public API is recorded for Semalytix.

What industry is Semalytix in?

Semalytix's product category is Pharmaceutical AI Analytics. Its primary akta.pro industry code is HLAJABAN, Data Integration, Interoperability & Reporting (ELR/HIE/CDC/NNDSS), with a secondary code of HLACAKAK, Medication Safety, Pharmacovigilance & Adverse Event Reporting IT. Its NAICS code is 6215 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireSemalytix Secures €5.7 Million to Scale its Agentic AI Platform, Bring Real-World Patient Insights into PharmaSemalytix GmbH, a German AI startup based in Bielefeld, announced the successful closing of a €5.7 million growth funding round led by Holland Capital, with participation from existing investors. The funding will be used to enhance the company's PatientGPT-powered Agentic AI platform, expand internationally into Europe and the USA, and grow its AI, customer success, and commercial teams. The company has already demonstrated commercial traction with several top-20 pharmaceutical companies, offering technology that transforms real-world patient data into actionable insights for drug development.SemalytixNews & UpdatesSemalytix, a German AI company specializing in pharmaceutical patient intelligence, announced the successful closing of a €5.7 million growth funding round led by Dutch venture capital firm Holland Capital. The company will use the proceeds to enhance its AI platform capabilities, expand internationally in Europe and the USA, and scale its operational and commercial teams to meet growing demand from pharmaceutical clients. The funding validates Semalytix's vision of revolutionizing patient insights generation through its PatientGPT-powered platform, which transforms unstructured patient data into actionable intelligence for drug development workflows.Nordic 9Semalytix picks up €2 million from NRW Bank in a series A capital extensionSemalytix, a German developer of an intelligence platform for patient needs research, secured €2 million from NRW Bank. The funding extends its 2020 series A round. The company's Pharos platform serves customers including Boehringer Ingelheim.